TABLE 3.
ARESdb prediction statisticsa
| Compound | CA | VME | ME | mE |
|---|---|---|---|---|
| Aztreonam | 89.5% (34 of 38) | 3.3% (1 of 30) | 0.0% | 7.9% (3 of 38) |
| Cefepime | 92.1% (35 of 38) | 0.0% | 0.0% | 7.9% (3 of 38) |
| Ceftazidime | 86.8% (33 of 38) | 6.7% (2 of 30) | 0.0% | 7.9% (3 of 38) |
| Ciprofloxacin | 100.0% (38 of 38) | 0.0% | 0.0% | 0.0% |
| Gentamicin | 89.5% (34 of 38) | 6.3% (2 of 38) | 20.0% (1 of 5) | 2.6% (1 of 38) |
| Levofloxacin | 97.4% (37 of 38) | 0.0% | 0.0% | 2.6% (1 of 38) |
| Meropenem | 97.4% (37 of 38) | 3.1% (1 of 32) | 0.0% | 0.0% |
| Piperacillin-tazobactam | 84.2% (32 of 38) | 10.0% (3 of 30) | 0.0% | 7.9% (3 of 38) |
| Tobramycin | 94.7% (36 of 38) | 3.1% (1 of 32) | 16.7% (1 of 6) | 0.0% |
| Overall | 92.4% (316 of 342) | 3.7% (10 of 269) | 4.3% (2 of 47) | 4.1% (14 of 342) |
aCA, categorical agreement; VME, very major error; ME, major error; mE, minor error.